Novartis Animal Health
Australasia Pty Limited
54 Waterloo Road
North Ryde
NSW 2113
1/2
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG
Launch of ZOLVIX
®
revolutionises sheep worm control
Novartis Animal Health today announced the official Australian launch of
ZOLVIX
®
(monepantel), from the new Orange Drench Class – the first new class
of sheep drench since the 1980s.
To view the Multimedia News Release, please click below:-
af74d65b2da1
Sydney, August, 30, 2010 — Novartis Animal Health today announced that on
1 September 2010 ZOLVIX, a revolutionary sheep drench and the first product from the
new class of anthelmintics called the Amino-Acetonitrile Derivatives (AADs), will be
officially launched in Australia.
ZOLVIX contains the active ingredient monepantel which has a novel, nematode specific
mode of action. ZOLVIX kills >99.9% of worms, including those resistant to existing
anthelmintic (drench) classes. No ZOLVIX resistant worm populations exist in the field.
Currently available drenches have been a valuable resource in the battle against gastro-
intestinal worms; however, increasingly worms are becoming resistant to these older
treatments, which means their performance is reduced and producers may incur
productivity and financial losses.
Australia is one of the global leaders when it comes to resistance, with sheep drench
resistance present on more than 90% of farms, in many cases to more than one drench
class.
ZOLVIX is the first truly novel drench for sheep in more than two decades and is the first
from the new AAD or orange drench class. It is highly effective against worms, including
worms whose resistance to existing drenches threatens both the profitability and
sustainability of sheep farming.
Dr. Brown Besier, Principal Veterinary Parasitologist in the Department of Agriculture and
Food Western Australia said, “This new anthelmintic is urgently needed, as drench
resistance affects almost all sheep farms in Australia. The new product will be of major
benefit itself, and will take the pressure off other drench classes as well.”
Dr. Justin Bailey, Technical Services Veterinarian, Novartis Animal Health, supported
these comments, “By integrating ZOLVIX into their drenching program this season sheep
producers will have the peace of mind that they are killing >99.9% of worms regardless of
their drench resistance status. This will maximise the health and productivity of their flock
now and into the future”.
Novartis Animal Health has also launched the Optimum™ drenching system, which
consists of the new, award-winning Optiline
®
drencher and Optivix
®
backpack,
both of
which were created in close cooperation with sheep producers and industry experts.
2/2
The Optiline drencher has been ergonomically designed to make it easy to use, with the
welfare of both the animal and user in mind. Altogether, the new drenching system is a
ground-breaking step forward in making drenching less of a hassle for sheep producers
and ensuring that the correct dose of ZOLVIX is given to sheep every time.
Rod Walker, Simcro Executive Director said, “Novartis had the vision to insist that a
radical new drench deserved an innovative new drench gun. They also had the courage
and the confidence that Simcro could transform a drench gun concept into a highly
regarded and practical product. And so the Optiline drencher was born.”
ZOLVIX will be available from leading rural resellers around Australia from 1 September
2010. For more information on ZOLVIX contact 1800 ZOLVIX (1800 965849) or visit your
rural reseller.
Disclaimer
This release contains certain forward-looking statements relating to the Group's business, which can be identified by
terminology such as “highly effective”, “unique”, “revolutionise”, “novel”, or similar expressions, or by express or implied
discussions regarding potential new products, potential new indications for existing products, or regarding potential future
revenues from any such products, or potential future sales or earnings of the Novartis Group or any of its divisions or
business units; or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on
these statements. Such forward-looking statements reflect the current views of the Group regarding future events, and
involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different
from any future results, performance or achievements expressed or implied by such statements. There can be no
guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for
existing products in any market, or that such products will achieve any particular revenue levels. Nor can there be any
guarantee that the Novartis Group, or any of its divisions or business units, will achieve any particular financial results. In
particular, management's expectations could be affected by, among other things, uncertainties involved in the
development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing
clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally;
the Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the
uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing
and other political pressures; the impact that the foregoing factors could have on the values attributed to the Group's
assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and factors referred to in
Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in these
materials as of this date and does not undertake any obligation to update any forward-looking statements as a result of
new information, future events or otherwise.
About Novartis Animal Health
Novartis Animal Health researches, develops and commercialises leading animal treatments that meet the needs of pet
owners, producers and veterinarians. Headquartered in Basel, Switzerland and present in almost 40 countries, Novartis
Animal Health employs about 2,600 people worldwide. For more information, please visit www.ah.novartis.com
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on
healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic
pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with
leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net
income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group.
Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent
associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com
ZOLVIX
®
,Optiline
®
and Optivix
®
are
registered trademarks and OptimumTM
is a trademark of Novartis AG, Basel,
Switzerland. Novartis Animal Health, 54 Waterloo Road, North Ryde NSW 2113.
# # #
Media Contacts:
Justine Mackay, Publicis Life Brands Sarah Reed, Publicis Life Brands
+612 9006 2944 (direct) +612 9006 2940 (direct)
+614 3532 5954 (mobile) +614 2132 7366 (mobile)
justine.mackay@publicislifebrands.com.au sarah.reed@publicislifebrands.com.au
NEWS 
